Noninvasive Traumatic Brain Injury Diagnostic Equipment Market Size, Share, Growth by 2030

The market for non-invasive diagnostic equipment for traumatic brain injuries (TBI) is projected to expand from US$ 1.349 billion in 2022 to US$ 3.541 billion by 2030.

The growth of this market is driven by the increasing need for sophisticated diagnostic tools and the demand for rapid and accurate diagnoses for TBI patients. However, the negative effects associated with contrast agents can hinder market expansion.

Growth Drivers:

Rapid and Accurate Diagnosis for TBI Patients Fuels Market Growth

One of the significant challenges in treating TBI is the frequent occurrence of undiagnosed or misdiagnosed cases. Traditionally, TBIs and concussions were identified using diagnostic tools like computed tomography (CT) scans and various neurological assessments. Unfortunately, the use of CT scans carries a risk of cancer due to radiation exposure. Therefore, achieving a swift and precise diagnosis of brain injuries is crucial for addressing both mild and severe cases. In October 2023, the Biomedical Advanced Research and Development Authority (BARDA) announced a partnership with GE Healthcare to create a new artificial intelligence (AI)-enhanced ultrasound technology aimed at facilitating the rapid diagnosis of traumatic injuries. Additionally, BARDA will assist GE Healthcare in developing a portable ultrasound system to improve disaster readiness and provide quick trauma care during mass casualty events. Consequently, advancements in technology are anticipated to introduce new trends in the non-invasive traumatic brain injury diagnostic equipment market in the near future.

Rise of Portable Non-invasive Monitoring Devices for TBI Diagnosis

Innovative non-invasive techniques for monitoring tissue metabolism are emerging, which can significantly enhance the diagnosis and management of brain conditions such as concussions, strokes, and TBIs, leading to faster patient recovery. The financial burden of TBI on healthcare systems is substantial, amounting to approximately US$ 76.5 billion annually, as reported by a white paper from BrainScope. Implementing "BrainScope One" in more affordable healthcare settings, such as emergency departments and urgent care centers, could potentially lower healthcare costs by up to 32.2%, according to the findings in the white paper. This device helps to reduce unnecessary CT scans, thereby decreasing the overall healthcare expenses associated with TBI. Thus, advancements in the diagnosis and monitoring of brain conditions are likely to create new opportunities for growth in the non-invasive traumatic brain injury diagnostic equipment market in the coming years.

Report Segmentation and Scope:

The analysis of the "non-invasive traumatic brain injury diagnostic equipment market" has been conducted by examining the following segments: technique, device type, and end user.

Non-invasive Traumatic Brain Injury Diagnostic Equipment Market by Technique:

The market is categorized by technique into several segments, including electroencephalography, eye tracking and near-infrared spectroscopy, magnetoencephalography, transcranial magnetic stimulation, cerebral metabolic rate of oxygen, magnetic resonance imaging (MRI), intracranial pressure monitoring, brain-computer interfaces, and others. In 2022, the magnetic resonance imaging segment held the largest share of the market. The eye tracking and near-infrared spectroscopy segment is expected to exhibit the highest compound annual growth rate (CAGR) of 14.3% during the forecast period.

Non-invasive Traumatic Brain Injury Diagnostic Equipment Market by Device Type:

The market is divided into imaging devices and monitoring devices. The imaging devices segment accounted for a larger share of the market in 2022, while the monitoring devices segment is projected to achieve a higher CAGR of 14.5% throughout the forecast period.

Non-invasive Traumatic Brain Injury Diagnostic Equipment Market by End User:

The market is segmented by end user into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment dominated the market in 2022, while diagnostic centers are expected to experience the highest CAGR of 13.4% during the forecast period.

Strategic Developments:

The forecast for the non-invasive traumatic brain injury diagnostic equipment market can assist stakeholders in formulating their growth strategies. Below are some strategic initiatives undertaken by key players in the market:

- In April 2022, Imeka partnered with GE Healthcare to enhance magnetic resonance imaging (MRI) capabilities and advance precision medicine for brain health. GE will incorporate Imeka's non-invasive neuroimaging technology into the BrainWave advanced diffusion processing, enabling detailed analysis of brain injuries through MRI signals.

Competitive Landscape and Key Companies:

Prominent companies in the non-invasive traumatic brain injury diagnostic equipment market include GE HealthCare Technologies Inc, Elekta AB, Integra LifeSciences Holdings Corp, Natus Medical Inc, Raumedic AG, BrainScope Co Inc, Luciole Medical AG, Soterix Medical Inc, Medtronic Plc, Vivonics Inc, NanoDx Inc, Compumedics Ltd, Sense Diagnostics Inc, NeuraSignal Inc, and Neurovigil Inc. These companies are focused on developing new technologies, enhancing existing products, and expanding geographically to meet the rising global demand. For instance, Sense Neuro Diagnostics received clearance to conduct clinical trials for hemorrhage detection, with a new trial approved by the FDA Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices starting in June 2023, involving up to 300 patients across 30 sites in the US, Canada, and India. This non-invasive technology can gather 360 data points in just 2.5 seconds to identify brain hemorrhages or stroke types, facilitating rapid responses from healthcare professionals, emergency teams, neuro ICU staff, and military field hospitals assessing and monitoring TBI. Furthermore, innovative product launches by US-based companies aimed at improving diagnostic outcomes for TBI patients are expected to drive growth in the non-invasive traumatic brain injury diagnostic equipment market.